38
The
th Annual Meeting of April 8-9, 2017 The Endocrine Society and The Diabetes Association of the R.O.C. (Taiwan)
LS1
ADVANCES IN INSULIN AND LIPID MANAGEMENT: GLARGINE U300 AND PCSK-9 INHIBITOR INSULIN GLARGINE U300: THE NEXT GENERATION BASAL INSULIN TO REDEFINE THE LIMITS OF CONTROL CHIA HUNG LIN Division of Endocrinology and Metabolism, Chang Gung Memorial Hospital
,QVXOLQ JODUJLQH 8 *OD ZDV WKH ¿UVW ORQJ DFWLQJ EDVDO LQVXOLQ DQDORJ WR EH LQWURGXFHG into clinical practice and it remains the most widely used. Although Gla-U100 is an effective and safe treatment, there are still many unmet needs in current clinical practice. The higher concentration of LQVXOLQ LQ JODUJLQH 8 *OD UHVXOWV LQ D GLVWLQFW SKDUPDFRNLQHWLF DQG SKDUPDFRG\QDPLF SUR¿OH Gla-U300 has a longer duration of action than U100 and plasma insulin exposure is less variable. The Phase III EDITION clinical trials indicated that Gla-U300 offers a similar level of glycaemic control to U100 but with a lower rate of hypoglycaemic events, in particular nocturnal episodes. Patient-level meta-analysis of EDITION 1, 2 and 3 shows the comparable glycemic control with K\SRJO\FHPLD EHQH¿W ZLWK *OD DQG *OD UHJDUGOHVV RI DJH %0, GLDEHWHV GXUDWLRQ DQG eGFR subgroup at baseline. In a real-world assessment of patient characteristics and clinical outcomes of early users of the new insulin Gla-U300 in the US, switching to Gla-300 from other basal insulins was associated with improved glycemic control and a trend towards less hypoglycemia in patients with T2DM after 6 months. Through the upcoming symposium, we will be sharing “real world” case studies of local Taiwan clinical experiences with the next generation insulin Gla-U300, including T2DM patients on Gla-U300 switched from OADs uncontrolled, and other basal insulin uncontrolled. Taken together, the data suggests that Gla-U300 represents an overall better treatment option. While Gla-U300 and Gla-100 exhibit equally strong efficacy, more importantly, Gla-U300 with its VDIHU DQG PRUH VWDEOH EORRG JOXFRVH FRQWURO SUR¿OH SURYLGHV 7DLZDQ +&3V DQG SDWLHQWV WKH FRQ¿GHQFH WR DWWDLQ PRUH RSWLPDO JO\FHPLF JRDOV WKURXJK UHGH¿QLQJ WKH OLPLWV RI )3* FRQWURO
90
